MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets GoalZacks Investment Research • 06/24/25
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and PreventionBusiness Wire • 06/24/25
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)Business Wire • 06/23/25
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate CancerBusiness Wire • 06/18/25
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?Zacks Investment Research • 06/17/25
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025The Motley Fool • 06/14/25
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single AgentBusiness Wire • 06/13/25
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for DogsBusiness Wire • 06/12/25
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025Business Wire • 06/12/25
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?Zacks Investment Research • 06/11/25
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25